Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model

Cancer Letters

Volumn 247, Issue 1-2, 2007, Pages 143-149

  Zhang, Xuefeng ^a   Connolly, Caitlin ^a   Duquette, Mark ^a   Lawler, Jack ^a   Parangi, Sareh ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Anti angiogenic therapy; Continuous administration; Orthotopic model; Pancreatic cancer; Thrombospondin 1

Indexed keywords

RECOMBINANT PROTEIN; THROMBOSPONDIN 1; THROMBOSPONDIN 1 TYPE 1 REPEAT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR BLOOD FLOW; VASCULAR PATENCY;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; THROMBOSPONDIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845674173     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.04.003     Document Type: Article

References (19)

1. McKenna S., and Eatock M. The medical management of pancreatic cancer: a review. Oncologist 8 (2003) 149-160
2. Khan A.W., Dhillon A.P., Hutchins R., Abraham A., Shah S.R., Snooks S., and Davidson R. Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eur. J. Surg. Oncol. 28 (2002) 637-644
3. Ikeda N., Adachi M., Taki T., Huang C., Hashida H., Takabayashi A., et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer 79 (1999) 1553-1563
4. Kisker O., Becker C.M., Prox D., Fannon M., D'Amato R., and Flynn E. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61 (2001) 7669-7674
5. Raut C.P., Takamori R.K., Davis D.W., Sweeney-Gotsch B., O'Reilly M.S., and McConkey D.J. Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol. Ther. 3 (2004) 679-687
6. Yanagi K., Onda M., and Uchida E. Effect of angiostatin on liver metastasis of pancreatic cancer in hamsters. Jpn. J. Cancer Res. 91 (2000) 723-730
7. Zhang X., Galardi E., Duquette M., Delic M., Lawler J., and Parangi S. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin. Cancer Res. 11 (2005) 2337-2344
8. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., and Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad Sci. USA 87 (1990) 6624-6628
9. Lawler J., and Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int. J. Biochem. Cell Biol. 36 (2004) 1038-1045
10. Capillo M., Mancuso P., Gobbi A., Monestiroli S., Pruneri G., Dell'Agnola C., et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin. Cancer Res. 9 (2003) 377-382
11. Morishita T., Mii Y., Miyauchi Y., Miura S., Honoki K., Aoki M., et al. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. Jpn. J. Clin. Oncol. 25 (1995) 25-31
12. Drixler T.A., Borel Rinkes I.H., Ritchie E.D., van Vroonhoven T.J., Gebbink M.F., and Voest E.E. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res. 60 (2000) 1761-1765
13. Miao W.M., Seng W.L., Duquette M., Lawler P., Laus C., and Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res. 61 (2001) 7830-7839
14. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., and Baluk P. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165 (2004) 35-52
15. Huang H., Campbell S.C., Bedford D.F., Nelius T., Veliceasa D., Shroff E.H., et al. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol. Cancer Res. 2 (2004) 541-550
16. Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L., et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol. 155 (1999) 441-452
17. Jin R.J., Kwak C., Lee S.G., Lee C.H., Soo C.G., Park M.S., et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther. 7 (2000) 1537-1542
18. Yee K.O., Streit M., Hawighorst T., Detmar M., and Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am. J. Pathol. 165 (2004) 541-552
19. Hansma A.H., Broxterman H.J., van der Horst I., Yuana Y., Boven E., Giaccone G., et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann. Oncol. 16 (2005) 1695-1701